The milestones of the history of medicine which we recognise are almost entirely related to the reduction of mortality or the al1eviation of morbidity, and most statistics are compiled from rates of birth and death and the incidence of specified diseases. There is little information on the contribution that can be made to the quality of life.
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With a persistent fall in the birthrate, obstetrics has been increasingly challenged to ensure that every pregnancy shall be fulfilled by perfection in the offspring. The first reaction to this challenge was to improve the conditions of childbirth beyond those required to preserve the life of the mother, and then to support the newborn without regard to the possible long-term adverse outcome if the child survived. For a short time, Herculean efforts were made to preserve the lives of infants with grave physical defects. However, this error has been rectified, and attention turned to the careful examination of the fetus from several points of view.
(a) its compatibility with its mother, and the placental transport of inimical maternal antibodies ; (b) the ability of the placenta to support the fetus; (c) the capability of the fetus itself to develop into a healthy child. Fetal-maternal incompatibility has now been largely overcome, so far as erythrocyte antigens are concerned, wherever there is an effective bloodtransfusion service. Although the existence of other forms of incompatibility cannot be ruled out, they cannot be of any great importance in so far as they remain undetected.
The adequacy of the placenta aroused speculation from early times. It was available for close inspection after every birth, and much attention was devoted to the anatomical manifestations of disordered function. The simple embryological fact that the placenta was essentially a part of the fetus seems to have been ignored by obstetricians until Diczfalusy conceived the notion of the 'feto-placental unit'. This concept re-orientated the views of hormone chemists, who were then able to explore the significance of maternal oestrogen excretion as a manifestation of the combined efficiency of the fetal adrenals and the placenta. A proper understanding of oestrogen metabolism was the key by which the chemist was able to enter the obstetrical world with information, otherwise unobtainable, that could influence the survival and health of the unborn child. The knowledge that oestrogen excretion by the mother provided an important index of fete-placental function, set in chain a host of investigations directed to securing the delivery of healthy babies, and only healthy babies. From monitoring the progress of the fetus in late pregnancy interest has also been directed towards the first trimester, when early warning of fetal abnormality can be used to secure easy abortion with minimal psychological trauma.
The literature on fetal monitoring is now so large and fast-growing that the present authors have been obliged to cut short their labours at what, in retro-spect, may prove to be a critical time. However, this review is offered in the hope that it will provide an adequate background against which the clinical chemist may exercise his choice of techniques and his interpretation of the results of his work, and that subsequent reviews may be written as logical continuations of this work.
STEROIDS

Maternal urinary oestrogens-s-methodology
The measurement of oestrogens in maternal urine is probably the most widely utilised test of fetal function in late pregnancy. Its application and its importance to obstetrics have been reviewed Macnaughton, 1967; Klepper, 1968) . The basis for its importance rests on the lOoo-fold increase in oestrogen excretion during normal pregnancy and the involvement of both the fetus and placenta in the biochemical mechanism for oestrogen production in late pregnancy (Cassmer, 1959; Diczfalusy, 1969) . It is during the final trimester that the greatest increase in oestriol production occurs, and oestrogen assays contribute little to the management of pregnancy prior to 30 weeks' gestation.
It is not appropriate to discuss in detail here the many alternative methods for the determination of oestrogens in pregnancy urine. Early methods for oestrogen estimation (Brown and Coyle, 1963; Klopper and Billewicz, 1963) were, in general, modifications of more laborious techniques developed for use with urine from non-pregnant women (Brown, 1955) . From the middle 1960's many methods have been introduced to measure 'total oestrogens' in pregnancy urine (Montagu, 1964; Oakey et al., 1967; Brown et al., 1968b) . The adjective 'total' is a misnomer, since many unstable oestrogens-for example, 2-hydroxyoestrone, 100.hydroxyoestrone-are destroyed during processing, but it emphasizes the point that no separation of the individual oestrogens is attempted in these methods. The techniques commonly involve hydrolysis of conjugates, followed by some degree of purification by solvent extraction, and a final colorimetric or fluorimetric step utilizing the Kober reaction (Kober, 1931) . There are many modifications of this reaction, but essentially it consists of heating the extracted oestrogens with a solution of sulphuric acid and a reducing agent such as hydroquinone, followed by dilution with water to give a red solution suitable for colorimetry. Corrections are normally made for variable non-specific chrornogens by the method of Allen (1950) . The chromogens may be extracted in chloroform containing p-nitro phenol or trichloracetic acid to give an intense fluorescence (Ittrich, 1958) providing greater specificity and sensitivity. Recently, partially automated techniques have been introduced (Ua Conaill and Muir, 1968; Dixon, 1969) , but the requirement for hydrolysis of oestrogen conjugates has been a stumbling block to full automation. The latest developments (Campbell and Gardner, 1971; Hainsworth and Hall, 1971) utilise the technique, first proposed by Ittrich, in which the Kober colour is developed by direct reaction with the conjugates in the urine in a manner similar to that described by Brombacher et al. (1968) and by Howarth and Robertshaw (1971) . By this means continuous flow systems have been devised which offer greater output and precision.
Some controversy has arisen concerning the adequacy of the assays which measure total oestrogen like substances. Klepper (1968) argues forcefully that only a specific determination of the predominant hormone, oestriol, should be carried out and contends that 'total oestrogen' methods are imprecise and therefore inadequate. General experience, however, does not bear out this contention as methods for the determination of total oestrogen appear to be no less nor more precise than determinations of oestriol. Brown and Coyle (1963) , for instance, reported that the mean between-batch coefficient of variation (CV) of their specific oestriol estimation was 11 % whereas that of a manual total oestrogen method (Oakey et al., 1967) assayed in duplicate on different days was also 11 % (n = 39) and automated procedures enable a CV of around 5 % to be achieved (unpublished results).
The advantage of rapid 'total oestrogen' methods is that they enable results to be returned to the ward promptly, so that early action can be taken, and the service can be made available to a larger number of patients. No clinical trial appears to have been carried out to compare the effectiveness, in terms of decreased perinatal mortality, of the two approaches, and until a significant benefit can be shown by the use of a specific method the assay of total oestrogen, properly carried out, has much to recommend it. Comprehensive reports on the application of the rapid fully automated techniques for total oestrogen are awaited with interest.
Many modifications of oestrogen assay techniques have been described in the literature reviewed here. These have been accompanied by different reference ranges and with varying claims for their specificity in measuring the oestriol component. In this review the terms 'normal ', 'subnormal', 'low', etc ., refer to the ranges devised by the authors in their own laboratories and the term 'oestrogen' has been used rather than 'oestriol' as this more correctly describes the steroids measured by the majority of methods. 85 2.1.1 Compounds which interfere with oestrogen assay Attempts to estimate the very low levels of oestrogen in urine of ovariectomized women showed that certain materials, particularly laxatives, can interfere with the determination of urinary oestrogens (Brown et al., 1957) . In pregnancy, where urinary oestrogen levels are much higher, the urine is assayed at greater dilution and interference from administered drugs presents a lesser problem. Glucose, at concentrations above 111 mmol/l, causes destruction of oestrogen during hydrolysis, but this problem can be minimised by testing urines with Clinistix and making appropriate dilutions. Oestrogen estimations are virtually impossible in pregnant patients who are being treated with Mandelamine (methenamine mandelate) for urinary tract infection Mackay et al., 1967; Eraz and Hausknecht, 1969) . Formaldehyde, which is released from this compound, reacts with the phenolic oestrogens to form tars.
Compounds which suppress oestrogen production
It is well established that absorption of corticosteroids by the mother may lead to reduced oestrogen excretion in pregnancy (Warren and Cheatum, 1967; Brown et al., 1968a; Scommegna et al., 1968) . The effect appears to be mediated through suppression of adrenocorticotrophin (ACTH) secreted by the fetal pituitary gland (Oakey, 1970a) . Consequently, oestrogen excretion in pregnant women taking corticosteroids for conditions such as asthma, sarcoidosis, or ulcerative colitis, may not reflect accurately the condition of the fetus (Wray and Russell, 1964; Simmer et al., 1966; Wallace and Michie, 1966; Brown et al., 1968a; Morrison and Kilpatrick, 1969; Driscoll, 1969; Oakey, 1970b) . Oakey (l970b) concluded that oestrogen excretion only reflected the condition of the fetus when the dose of cortisol (or equivalent) was less than 207 p,mol/d.
Recently penicillin has been implicated as a factor which reduces the plasma concentration and urinary excretion of oestrogen (Pulkkinen and Willman, 1971; Willman and Pulkkinen, 1971 ), although the mechanism by which this occurs is not understood. The chemical determination of oestriol was not affected by the urinary metabolites of the penicillin and the authors suggested that there may be some interference with oestrogen biosynthesis, metabolism, or excretion.
Renal function and urine volume
. The effect of renal function on oestrogen excretion has been investigated by two groups. Dickey et al. (1966b) noted that when patients in late pregnancy were in a supine position, there was a concomitant increase of both oestrogen excretion and glomerular filtration rate. Carrington et al. (1970) measured creatinine clearance and urinary and plasma oestrogens in subjects with renal impairment and concluded that the reduced excretion of oestrogen was due to poor renal function rather than low production. They suggested that creatinine clearance should be measured in patients with severe renal disease in order accurately to assess the significance of urinary oestrogen results. Treatment with diuretics, such as chIorthiazide, has been claimed to increase oestrogen excretion by Timonen et al. (1965) , but other workers (Bird and Reeves, 1969) were unable to confirm this finding in 11 uncomplicated pregnancies. Normal variations in urine output are not associated with changes in oestrogen excretion although massive hydration and diuresis may lead to increased oestrogen excretion (Timonen et al., 1965) . Frandsen (1963) surveyed data collected from women during routine hospital work and reported that the majority (72 %) of 24-h oestrogen excretions were within 20 %of the value for the preceding day. Bjoro (1972) found that in 63 %of his patients with uncomplicated pregnancies the daily variation was less than 20 %, but in 8 % the variation was about 45 %. Klepper et al. (1969) determined oestriol excretion for timed periods during six days in six women in a metabolic ward and found that the variation was inversely proportional to the length of the collection period. The coefficient of variation for a 24-h collection period was 17.9 %. In our experience (Oakey, unpublished observations) the greatest daily variations are seen in hypertensive patients. Although there is undoubtedly normal physiological variation in oestrogen excretion, a downward trend over three consecutive daily specimens should give rise to apprehension about the condition of the fetus, even when each successive value is within 20% of the preceding one.
Daily variation and timed urine collections
The use of 24-h urine reflects then a compromise between much shorter periods-for example, 2, 4, or 6-h-in which variability of oestrogen is high, and longer periods such as 48-h, which, although giving a more precise index of oestrogen excretion, involve both logistic and personal problems (Osofsky et al., 1970) . In an attempt to overcome the problem of incomplete urine collection it has been suggested that oestrogen excretion should be related to creatinine excretion. The daily excretion of creatinine in a normal adult is said to be approximately 8,8 mmol and to be independent of diet (Folin, 1905) , and it has been suggested that deviations from this value indicate gross failure to make a complete collection (Cummings et al., 1969) . Recent evidence from several laboratories has challenged the concept that daily creatinine excretion is constant (for example, Edwards et al., 1969) , and this has been confirmed with regard to pregnant women by Chattaway et al. (1969) . While gross deviations from complete collection may be recognized from measurement of urinary creatinine, comparison of urinary volumes with other specimens from the same patient often indicates failure to make a proper collection. Some workers (Watney et al., 1970) discount as inadequate all 24-h urine specimens of less than 1 litre, but this is an unusually rigorous standard.
Oestrogen-creatinine ratio on random urines
In efforts to ease the problems of urine collection and speed up the reporting of results it has been suggested that the oestrogen-creatinine ratio obtained from a random urine specimen might be used to predict the oestrogen excretion over a 24-h period (Dickey et al., 1966a; Pariente et al., 1971; Salvadori et al., 1971) . The last authors found that the coefficient of variation (CV) of the oestrogen creatinine ratios in successive 2-h urines (9-30 %) was less than the CV of successive 24-h oestrogen determinations, but the data suggest that oestrogen excretion for a 24-h period cannot be estimated confidently from the 2-h oestrogen-creatinine ratios. Strong evidence against using calculations of this kind was provided by Shelley et al. (1970) , who demonstrated that large discrepancies (from 35 % to 55 %) were found between the actual 24-h oestrogen excretion and that calculated from the oestrogencreatinine ratio of a single urine specimen passed during the same period. Discrepancies of this size are too great to be acceptable in planning obstetric action. The oestrogen-creatinine ratio has been used to detect a proportion (60%) of infants with subsequent low birth weights (Osofsky et al., 1971; Dickey et al., 1973) and the latter authors have shown that the predictive value is greatest prior to 28 weeks gestation. Although Mackay et al. (1968) concluded that the single specimen approach may 'have a place' in the assessment of fetal function, and Siddiqui and Watson (1971) went further in suggesting that 'the oestrogen-creatinine ratio determined on a small urine sample can be validly and accurately used as a fetal-placental function test', it does seem that more evidence of the type being collected by Rao (1974) is needed before oestrogencreatinine ratios can be used with confidence in the prediction of intrauterine fetal death.
Urinary oestrogen in the prediction of intrauterine fetal death
A number of early workers (Zondek and Goldberg, 1957; Ten Berge, 1960; Zondek, 1960; Greene and Touchstone, 1963) found that urinary oestrogen excretion was very low in women whose fetuses were already moribund. Later work (summarized in table 1) showed that in most cases in which intrauterine fetal death occurred after 32 weeks gestation, oestrogen excretion was low or falling prior to fetal death. 87 ographic technique (Brown and Coyle, 1963) . They described six: cases of fetal death occurring before the oestrogen results (which indicated fetal jeopardy) had been received from the laboratory. When rapid and frequent oestrogen assays are performed in patients selected on clinical grounds as being at risk (Beischer et al., 1968; Heys et al., 1968; Bjoro, 1972) those patients whose pregnancies are likely to end in fetal death can be identified. This is probably the most important use of oestrogen estimations. Perusal of the papers cited in table 1 shows that when maternal oestrogen excretion remains within the Statistical analysis was provided by Courey et al. (1969) , who found that the mean oestrogen excretion of 17 patients one to seven days prior to intrauterine death was significantly lower (p < 0.01) than that of 41 similar patients whose babies survived; and Nelson (1970) observed that of 85 oestrogen assays in 16 pregnancies which ended in perinatal death, 48 were more than 1 S.D. below the normal mean level for the time of gestation. Booth et al. (1965) , using a lengthy method and performing infrequent assays, concluded that the measurement of oestrogen excretion had little to offer in complicated pregnancies. They found low levels in pregnancies which culminated in stillbirths, but felt that in the majority of cases the clinical indications of fetal jeopardy were obvious before a fall in oestrogen levels was noticed.
The need for regular assays by a rapid method was demonstrated by Liggins and Evans (1963) , who measured oestrogen excretion by a lengthy chromat-normal range, the risk of intrauterine death is small even in patients classified as 'high risk': this includes those with suspected retarded fetal growth, toxaemia, and a poor obstetric history, but not those with Rhesus incompatibility. It has been suggested that early delivery of babies following subnormal oestrogen excretion may reduce the number of stillbirths, but produce infants with a high proportion of neurological and developmental handicaps (Wallace and Michie, 1966) and an increased number of neonatal deaths. In a group of 38 infants delivered prematurely following low oestrogen excretion, however, only four died in the neonatal period, whereas in a comparable group of 21 patients whose deliveries were not induced 14 infants died soon after birth (Heys et al., 1968) . With regard to neurological handicaps Greene et al. (1969) , in a careful study with suitable control patients, showed that delivery after subnormal oestrogen excretion did not predispose to developmental problems in comparison 88 with infants matched for birth weight and gestation period.
Urinary oestrogen in retarded fetal growth
Retarded fetal growth may result from a variety of factors. These include maternal pre-eclampsia, anaemia, or pyelonephritis; the effect of genetic, teratogenic, or infectious agents in the fetus; or 'placental insufficiency' caused by cord compression or underdevelopment and infarction of the placenta.
Growth retardation or placental insufficiency may often be suspected on clinical grounds when in fact the fetus is developing normally, In those reports (Strand, 1966; Michie, 1967; Galbraith et al., 1969) which include all suspected cases of growth retardation (table 2) it is clear that a large proportion of these pregnancies produce babies of normal weight. Oestrogen estimation is oflittle value in the diagnosis of retarded fetal growth, since normal oestrogens often precede delivery of a small baby and low oestrogen excretion may be followed by perinatal death of a baby of normal weight (table 2) . On the other hand, oestrogen estimations are of great value in the management of a patient once this condition is suspected. Low oestrogen excretion precedes most fetal deaths (Michie, 1967; Klapper, 1968) , whereas normal excretion is associated with few perinatal deaths (table 2) . Serial assays should therefore be used to follow the progress of any fetus suspected as being small-for-dates and to help in the prediction of possible fetal death.
Urinary oestrogen in toxaemia
Toxaemia, a condition characterised by raised blood pressure, with oedema and/or albuminuria superimposed, is a fairly common complication which develops late in pregnancy and which can lead to stillbirth or retroplacental haemorrhage. Toxaemia is a dynamic disease and it may occur with pre-existing essential hypertension or renal disease, and may present with different grades of severity. Few authors (table 3) have categorised these grades when studying oestrogen excretion but have generally grouped together all patients with some degree of hypertension at some stage of their pregnancy. One such report is that of Greene and Touchstone (1963) who nevertheless found low oestrogen excretion in 21 out of 32 patients including all 10 whose pregnancies ended in perinatal death. Prompt caesarean section yielded living babies in the other 11 patients with low oestrogen levels thus avoiding likely perinatal death. Michie (1967) made a careful study of oestrogen excretion in relation to the severity of toxaemia. In mild (blood pressure high on two occasions) and moderately severe (blood pressure high with oedema and proteinuria) toxaemia, the oestrogen excretion was rarely low unless the baby was small-for-dates or perinatal death occurred. In severe toxaemia however (blood pressure, oedema, or proteinuria highly abnormal) the oestrogen level was almost always low whether or not the infant survived. Heys et al. (1969) also showed that the proportion of patients with low oestrogen excretion was highest in the severe toxaemia group. When retarded fetal growth and severe toxaemia was present, and when fetal death subsequently occurred, all patients had low oestrogen excretion.
In patients with toxaemia, therefore, normal excretion is usually associated with live births, perinatal deaths are preceded by subnormal excretion, and falling levels coincide with deteriorating feto-placental function. Urinary oestrogen measurements are of most value in severe toxaemia and when retarded fetal growth is coexistent. Assays are necessary every one or two days in the late stages of these pregnancies if perinatal death is to be avoided and the optimum time for delivery accurately predicted.
Urinary oestrogen excretion in diabetic pregnancy
Diabetes is a serious complication of pregnancy and the associated 15%perinatal mortality (Echt and Cohen, 1970) is much higher than in the normal obstetric population. There are numerous manifestations of the disease in the pregnant patient. The fetus is often large and the placenta bulky and immature. The mother may have transient chemical or gestational diabetes or chronic overt diabetes, and she may have further complications such as toxaemia or diabetic glomerulosclerosis (affecting oestrogen clearance). Not all investigators have differentiated the grades of severity of the disease and the secondary complications, and this has probably resulted in some discrepancies regarding the significance of low oestrogen production and of normal levels in relation to fetal distress. The majority of authors have simply recorded the urinary oestrogen levels coincident with A report which did classify patients according to the severity of their diabetes was that of Rivlin et al. (1970) who examined oestrogen levels retrospectively in a large series of patients. They claimed that nine deaths (50 %) would have been preventable if the oestrogen results had been taken into account in the management of pregnancy. Five of these were neonatal deaths after elective early delivery following normal oestrogen levels, and four were intrauterine deaths when delivery was not performed although there had been a sharp decrease in oestrogen excretion. They also reported that in the group of chemical diabetics there were no instances of low oestrogen levels, except where further complications were manifest, and that the majority of assay results in the overt diabetic group were below the normal level. Easterling et al. (1970) identified two types of diabetic oestrogen patterns although they did not relate these to the severity of the disease. One pattern showed persistently low oestrogen levels which were of little value in determining the optimum time for delivery. This pattern was concomitant with low birth weight and high mortality rate. The other pattern, which showed normal rising levels, indicated a better prognosis, but occasional precipitous falls, suggesting the necessity for rapid intervention, could arise. Hobkirk and Nilsen (1962) and Cohen (1971) have shown that the unstable oestrogens-for example, the ring D o-ketols, such as 16a-hydroxyoestrone, and 2-hydroxyoestrogens-make up a greater proportion of the oestrogen excretion in diabetic than in uncomplicated pregnancies. As these steroids are easily destroyed during hydrolysis the apparent oestrogen excretion may be low in diabetic pregnancy although the overall oestrogen production is higher than normal. The predictive value of the oestrogen excretion may therefore be fortuitous in this situation.
In summary, oestrogen assays in diabetic patients can make an important contribution to the prevention of deaths due to prematurity, delivery being safely postponed while serial oestrogen patterns are satisfactory. Fetal distress, heralded by falling oestrogens can, however, occur rapidly and it is mandatory to monitor the levels everyone or two days. As the most common cause of neonatal death in these patients is respiratory distress syndrome, often due to early obstetric intervention, the concomitant assessment of fetal lung maturity (section 6.1) is of particular value.
Urinary oestrogen in prolonged pregnancy
Prolonged pregnancy itself is probably not inevitably associated with high perinatal mortality. When, however, the condition is associated with reduced liquor volume and/or meconium staining (often referred to as the postmaturity syndrome) then perinatal mortality is high even with large babies. Essentially, a test is required to differentiate prolonged pregnancy without fetal distress and prolonged pregnancy with postmaturity syndrome.
A number of workers have studied oestrogen excretion in pregnancies continuing beyond the 41st week. Some of these results are summarised in table 5. It is generally agreed that the levels of oestrogen excretion at term are sustained at a constant or slightly rising level in uncomplicated prolonged pregnancy. Infants with postmaturity syndrome are sometimes delivered of women with normal oestrogen excretion, but most workers are agreed that a considerably larger proportion of such infants are born to women with low oestrogen levels. The overlap between the two groups suggests, however, that oestrogen excretion data should be supplemented by other means of assessment.
Urinary oestrogen in Rhesus incompatibility
Efforts have been made to apply oestrogen determinations as an index of the severity of the fetal erythroblastosis, to aid in the timing of intrauterine transfusions, and to detect the likelihood of intrauterine death. Greene and Touchstone (1963) and recorded the failure of weekly assays of oestrogen excretion to predict impending fetal death in Rhesus iso-immunization. Klepper and Stephenson (1966) , Lundwall and Stakemann (1969) , and Taylor et al. (1963) found that while oestrogen excretion did not appear to relate to the severity of the fetal condition, in those cases associated with fetal death the levels were low or falling immediately prior to termination. Similarly Mandelbaum et al. (1970) reported that the mean level of oestrogen excretion in women whose babies survived was significantly greater than that in women whose babies died of erythroblastosis, although no claim was made that individual prognosis could be made. Bjerre et al, (1968) concluded from the results of a small series that intrauterine death due to Rhesus incompatibility did not occur when the urinary oestrogen level was stable or rising.
With regard to intrauterine transfusions, Michie and Robertson (1971) suggested that when this procedure did not result in a marked rise in oestrogen excretion, intrauterine fetal death was likely. Gordon, Crawford and Oakey (unpublished data), however, studied 54 patients and concluded that impending fetal death could not be predicted from the level of oestrogen excretion itself nor from changes in excretion following intrauterine transfusion.
Although there is some conflict of opinion, possibly due to the varying frequency of oestrogen assays, published reports suggest that the level of oestrogen excretion does not necessarily reflect the condition of the erythroblastotic fetus. This is perhaps understandable as the fetal defect lies in the haernopoietic system and changes in steroid metabolism may not occur until fetal damage is severe. Thus normal or possibly high levels do occur even in severely affected pregnancies and decreases in oestrogen excretion may occur only after fetal death.
Oestrogens in amniotic fluid
The means by which the concentration of oestrogens in amniotic fluid is regulated are less well understood than the processes leading to maternal excretion of these hormones, but the fetus evidently plays some part through swallowing the fluid and excreting the hormones. A careful study by Michie and Livingstone (1969) demonstrated that the amniotic fluid oestrogen concentration increases during the course of a normal pregnancy, especially after 36 weeks of gestation. Near term however, the 91 concentration of oestrogen remains steady, at least over a period of two days after rupture of the membranes (Biggs and Klepper, 1969) .
It was first suggested by Schindler et al. (1967) that the assay of oestrogen in amniotic fluid may provide a more valuable index of the status of the fetus than does the measurement of maternal oestrogen excretion. This thesis was based on the assumptions that amniotic fluid samples can be obtained without delay and that the liquor is 'nearer' to the fetus than is the maternal urine. These workers presented evidence that the concentration of oestrogens in amniotic fluid was low when the fetus was severely affected but their data suggested that low oestrogen values were also encountered in many patients whose babies survived.
Most reports of amniotic fluid oestrogen concentrations in 'at risk' pregnancies have been related to Rhesus incompatibility. This is probably because amniocentesis is an accepted part of the management of these patients, especially if intrauterine transfusion of the fetus is to be carried out. In addition, measurement of urinary oestrogens in this condition does not provide a clear cut indication of fetal function (2.1.11) and hence other ways have been sought to monitor the fetus.
In studies restricted to small series, Berman et al. (1968) and Aleem et al. (1969) observed low liquor oestrogen concentrations in patients with severe Rhesus iso-immunisation.
Rather different conclusions were reached by Michie and Robertson (1971) who measured liquor oestrogen levels at regular intervals in five pregnancies with severely affected infants. Virtually all results were within one standard deviation of the mean level for mildly affected babies, and in five cases where affected babies died in the neonatal period only two patients had low concentrations of oestrogen in the liquor.
Preliminary precipitation of oestrogens with ammonium sulphate is believed to protect the labile oestrogens from destruction during acid hydrolysis (Cohen, 1966) , and this technique was used by Pinkus and Pinkus (1970) to study fluid from women whose pregnancies were complicated by Rhesus iso-immunisation, intrauterine fetal death, or anencephaly. They found no difference between oestrogen concentration in these women and that in liquor from women with normal pregnancies. Clearly, the value of liquor oestrogen assays is not resolved although two important factors should be considered. Firstly, hydramnios is often a complicating factor in pregnancies with Rhesus incompatibility and the degree of hydramnios often reflects the severity of the complication. It is possible therefore that the reduced oestrogen concentration may merely reflect excessive volumes of liquor, and it would be helpful if reports of liquor volumes were included in accounts of the technique. Secondly, methods for the determination of oestrogen in amniotic fluid are by no means reproducible between laboratories (Klopper et al., 1971) , and this factor may account for some of the discrepancies noted. In view of the inherent risks in amniocentesis and the advantages of urinary and plasma assays it is unlikely that the investigation of amniotic fluid oestrogens as an index of fetoplacental function will be pursued.
Oestrogens in peripheral plasma
Maternal urinary oestrogens provide an integrated value over a finite time period (with inevitable delay while the specimen is collected), whereas plasma oestrogen levels reflect production at a single point in time but have the advantage that the sample may be obtained instantaneously. Until recently, methods for the estimation of oestrogens in plasma were available but not widely utilised because the methods were long and intricate (Roy and Brown, 1960; Preedy and Aitken, 1961) and the sensitivity was such that fairly large volumes of blood were required. Two developments have changed this situation. Firstly, the introduction of f1uorimetric methods which offer a more sensitive end point for the assay (Nachtigall et al., 1966) ; secondly, the introduction of even more sensitive protein binding and radioimmunoassay techniques, some of which are capable of measuring specific oestrogens in their conjugated and/or unconjugated forms.
A competitive binding method using rabbit uterine cytosol was devised for oestriol by Corker and Naftolin (1971) . These workers measured total oestriol after acid hydrolysis and solvent partition. Masson (1973a) devised a similar method using an antiserum rather than a receptor protein. Gurpide et al. (1971) used a non-specific antiserum reacting with a variety of oestrogens to measure total oestrogens without prior hydrolysis or extraction. Much of the emphasis however has centred on the measurement of unconjugated oestrogens, possibly because they are more easily extracted from plasma. Competitive protein binding methods have been devised for unconjugated oestriol by and for unconjugated oestradiol-17,8 by Sylbuski (1971) and Tulchinsky and Koreman (1971) , while radioimmunoassay has been used for unconjugated oestriol by Tulchinsky et al. (1972) and for unconjugated oestrone and oestradiol-17,8 by de Hertogh (1973) .
Whichever form of oestrogen is measured, it is important to know if the concentration found in a single plasma sample reflects the daily production, or whether rapid changes in concentration occur which render the approach valueless. Selinger and Levitz (1969) reported that 18 out of 25 patients showed plasma total oestriol concentrations which were consistently about 25 % lower in samples collected at 16.30-h than in samples collected at 08.00-h or 21.3Q-h. Subsequently these workers were unable to confirm these results in another group of patients (Levitz et al., 1974) . A small diurnal variation (approximately 10%) was noticed in three out of five patients by Macourt et al. (1971) who claimed that it was not great enough to preclude the use of the method for clinical assessment of the fetoplacental unit. A lack of diurnal variation has also been reported for plasma unconjugated oestradiol-17,8 (Tulchinsky and Korenman, 1971 ) and unconjugated oestriol ) and for plasma total oestriol (Masson and Wilson, 1972) . In contrast to the general consensus, Townsley et al. (1973a) detected a significant diurnal rhythm in both plasma unconjugated oestradiol-17,8 and total oestriol in a carefully constructed experiment on seven samples taken at four-hourly intervals from each of 22 women. The oestrogen levels were maximum at 12.00-h and minimum at 24.00-h. It is still not clear therefore if there is a significant variation in plasma oestrogen concentration over a 24-h period.
Although they recorded coefficients of variation of 8-18 % on samples taken serially during the day from the same patient, Masson and Wilson (1972) found no significant fluctuation in total oestriol levels after meals, exercise, and rest. This was in agreement with the results of Macourt et al. (1971) , who recorded less than 12.5 % variation in patients without renal problems in similar circumstances, but differed from those of Roy (1962) who had earlier concluded that hospitalization and bed rest resulted in a fall in plasma total oestrone and total oestradiol-17,8.
Day-to-day variations of between 5 % and 13% (CV) have been reported for total oestriol (Macourt et al., 1971; Masson and Wilson, 1972) , for unconjugated oestradiol-17,8 (Chan and Klopper, 1974; Klopper and Shaaban, 1974) , and for conjugated oestradiol-17,8 (Chan and Klepper, 1974) . These variations are lower than those generally reported for urinary oestrogens.
Some information on the prognostic value of plasma oestriol levels was provided by Nachtigall et al. (1968) using a f1uorimetric technique. The plasma total oestriol concentrations in seven patients with severe toxaemia and small-for-dates babies were in the lower part ofthenormal range andshowed little tendency to increase after 34 weeks gestation, while very high levels were recorded in three patients whose toxaemia was complicated by nephrotic syndrome. Six patients with mild toxaemia who were delivered of normal babies showed plasma oestriol concentrations within the normal range, but distinguishable from those with more severe complications. Of six patients with severe diabetes, five had normal oestriol concentrations and the other patient who had low oestriol levels lost her baby in the neonatal period. Another patient in this group showed falling values, within the normal range, prior to delivery of a small baby by caesarean section. Roy and Kerr (1964) also found plasma oestrogen concentrations within the normal range in eight women whose pregnancies were complicated by diabetes although in another diabetic patient, whose baby died in utero, low levels were observed. Nachtigall et al. (1968) found low plasma oestriols in all nine cases of suspected intrauterine death which were later confirmed, but as these fetuses were probably dead at the time the specimen was collected, the authors agree that the prognostic value cannot be assessed from this evidence. Roy et al. (1963) , however, found low concentrations immediately prior to intrauterine fetal death in four patients.
Oestriol has also been measured in peripheral plasma by gas liquid chromatography (GLC) after extensive purification of extracts . Normal values were found in Rhesussensitised pregnancies and low values were noted after fetal death in utero. Values were found to rise on hospitalisation in contrast to the earlier observations of Roy (1962) . Fisher-Rasmussen (1971) also used GLC to measure plasma oestriol in 15 women whose babies subsequently showed fetal asphyxia (11) or were stillborn (4). Plasma oestriol was low in the only two cases of intrauterine death where the estimation was performed while the fetus was alive, although some patients with surviving infants had lower levels of plasma oestriol than did those whose babies were already dead.
Using competitive binding techniques, Loriaux et al. (1972) demonstrated a gradual increase in the concentrations of plasma oestrone sulphate and unconjugated oestrone, oestradiol-17f1, and oestriol during pregnancy and they suggested that anyone of these indices might be satisfactory for monitoring feto-placental function. The situation does not appear to be so simple, however. found a marked reduction in plasma unconjugated oestriol in cases with placental insufficiency and low levels associated with all six pregnancies which terminated in fetal death. They reported that their assay gave no indication of the state of the fetus in Rhesus iso-immunization. A study of nine insulin-dependent diabetics was undertaken by Masson and Sutherland (1973) , who found that 93 plasma total oestriol values were generally lower than in uncomplicated pregnancies. They felt however, that the results in diabetic patients should be interpreted with caution, and refer to a case where a sudden decrease in plasma oestriol occurred at 33 weeks prior to spontaneous delivery of a normal healthy infant one week later. After studying 18 patients with retarded intrauterine fetal growth Masson (1973b) reported gradually increasing, though lower than normal, plasma total oestriol values for normotensive patients and a flat low curve for the four hypertensive patients in the group. In this small series, he could not show a significant difference in the incidence of fetal distress in those patients with rising, constant, or falling plasma oestriol levels. After a comparative study of serum total oestriol and urinary oestrogens in 20 pregnant women, Dubin et al. (1973) concluded that the use of serum oestriol assays was not justified in the management of high-risk pregnancies. Neither could Townsley et al. (1973b) recommend serum unconjugated oestradiol-17f1 as an index. In particular, serum oestradiol-17f1 was low in five out of seven patients with normal urinary oestrogen excretion who delivered surviving infants of normal birth weight. Levitz et al. (1974) also noted a 70% fall in plasma total oestriol in a successful pregnancy.
Thus there is considerable evidence that plasma oestrogen levels do not always provide an accurate prognostic guide to the outcome of the pregnancy; there is no clear demonstration of which plasma oestrogen provides the best indicator of fetoplacental function; and the problem of diurnal variation has yet to be resolved. There has not yet been a properly designed study to show the value of the estimation of any oestrogen in blood in the prediction of the likelihood of intrauterine death in late pregnancy. Assays of oestrogen in urine have an assured role in this respect, and much harm might be done if estimations of oestrogens in plasma were uncritically substituted for urinary assays. More exhaustive studies to determine the value of plasma oestrogen assays for the assessment of fetal function and the identification of impending fetal death are required before the widespread adoption of plasma assays can be recommended.
Pregnanediol in maternal urine
Progesterone is produced in large quantities by the placenta (Cassmer, 1959) and is metabolised by the mother and excreted in the urine as pregnanediol. The fetus has little part to play in this pathway, and the measurement of pregnanediol is therefore almost entirely a test of placental function. Early studies were bedevilled byinadequate methods for measuring pregnanediol, but the development of more specific techniques utilising alumina chromatography (Klopper et al., 1955) , and gas chromatography (Podmore, 1966) following derivative formation, have enabled a more reliable assessment of the value of pregnanediol assays in obstetrics. Values for normal pregnancies have also been estimated by colorimetric assays (Coyle et al., 1956; Shearman, 1959; Klopper and Billewicz, 1963) .
Using a chromatographic technique, found a coefficient of variation of approximately 20 % for day to day pregnanediol excretion although Coyle et al. (1956) had earlier reported little day to day variation.
Urinary pregnanediol in retarded fetal growth
There have been few studies of pregnanediol excretion as a pointer to impending fetal death. This might be expected since the fetus plays a relatively minor role in the biosynthesis of progesterone and the production of pregnanediol. Russell et al. (1960) described 58 patients with suspected 'placental insufficiency' who had histories of hypertension, preeclampsia, small-for-dates babies, or previous stillbirths. Of 16 patients with suspected retarded fetal growth, 14 showedsubnormal pregnanediolexcretion, but the birth weights of the infants were not recorded. Another 14 patients were judged to have a fetus of normal size and only one, who subsequently produced a live infant, had subnormal pregnanediol excretion. One stillbirth occurred in a patient with normal pregnanediol values in this group. The diagnosis of placental insufficiency was uncertain in the remaining 28 patients although 15 had pregnanediol excretion below the normal range and four of these pregnancies resulted in perinatal death. Brush et al. (1966) studied 20 patients with suspected retarded fetal growth who showed normal pregnanediol excretion. Eighteen of these patients were delivered of babies of normal size and two of small-for-dates infants. On the other hand, of six patients with subnormal pregnanediol excretion, four produced small-for-dates infants (including two still births) and two delivered babies of normal weight. However, since Coyle et al. (1962) recorded normal levels of urinary pregnanediol in two patients with fetal death, some reservation must be exercised regarding the use of pregnanediol excretion in the detection of fetal death in utero. Brush et al. (1966) studied the pregnanediol excretion of women whose pregnancies were complicated by toxaemia and found that a normal, steady, or rising pregnanediol excretion was always associated with babies of normal weight. On the other hand, half the babies born after low or falling pregnanediol values were of low birth weight. A more extensive study was made by Strand (1966) , who noted that of 46 patients with pre-eclampsia and low pregnanediol excretion eight were delivered of small-for-dates babies, and there were 13 perinatal deaths. Urinary oestriol excretion was also measured and it is interesting to note that decreased pregnanediol excretion was preceded by low oestriol levels. In toxaemic patients with normal pregnanediol excretion, only 3 % of the infants were small-fordates. Keller et al. (1971) compared a number of fetal function tests in toxaemic patients and found that pregnanediol excretion predicted correctly 98 % of cases with normal feto-placental function but only 21 % of cases with abnormal function. These authors concluded that the test was unsuitable for monitoring at-risk pregnancies. Strand (1966) measured pregnanediol excretion in prolonged pregnancy in 60 patients. He reported that 37 %showed low pregnanediol excretion at term but in only three of these did the infant show signs of distress at delivery, as did two infants where there had been normal pregnanediol excretion.
Urinary pregnanediol in toxaemia
Urinary pregnanediol in prolonged pregnancy
It is now generally agreed that urinary pregnanediol is not a satisfactory indicator of feto-placental function.
Progesterone in maternal plasma
The assay of this hormone as an index of fetal function in the later stages of pregnancy has received little attention, although a number of techniques for its estimation are available. These include ultraviolet absorption (Short and Levett, 1962) , gas liquid chromatography (Sommerville et al., 1963; Van der Molen and Groen, 1965) , and competitive protein binding methods (Neill et al., 1967) . Coyle et al. (1962) found that plasma progesterone levels followed the trend of urinary oestriol excretion rather than that of urinary pregnanediol, but paradoxically, gave no warning of impending fetal death in two cases of severe toxaemia. There are many reports-for example, Lurie et al. (1966) -of plasma progesterone assays during induced abortion in early pregnancy. Even when the fetal heart beat has ceased, significant changes often do not occur until the placenta has separated. Thus, in early pregnancy the death of the fetus is not necessarily associated with marked alterations in maternal peripheral progesterone concentration.
These results, and the recognition that the fetus plays a minor role in progesterone synthesis, suggest that measurements of plasma progesterone are unlikely to provide useful information relating to fetal prognosis.
Dynamic tests for feto-placental function
In several endocrine disorders the use of steroid hormone assays has progressed from assays of urinary excretion or plasma concentration to function tests, where changes in hormone levels in response to an appropriate stimulus are measured. Such tests have been suggested for assessing the function of the feto-placental unit. Hausknecht and Mandelman (1969) studied the reserve capacity of the placenta to convert dehydroepiandrosterone to oestrogen in normal pregnancies and in women with small-far-dates fetuses. A loading dose of dehydroepiandrosterone sulphate was administered into the amniotic cavity and oestrogen was determined in maternal urine. Four patients with normal pregnancies excreted 12 %of the dose as oestriol within two days, whereas two patients with small-for-dates fetuses excreted about 5 % of the dose. However, if the changes are expressed in terms of pre-test oestrogen excretion, both groups of women had the same reserve potential for steroid metabolism and excretion, the second group merely having small placentas. This conclusion could have been derived from the pre-test oestrogen excretion alone. Keller et al. (1971) , also using the dehydroepiandrosterone sulphate loading test, found 30 % false predictions in both severe feto-placental dysfunction and in a group of normal pregnancies. In similar experiments urinary excretion of oestriol after intra-amniotic administration of oestriol sulphate was not significantly different in women with normal pregnancies and in those who were delivered of small-fordates babies (Klopper and Dennis, 1969) .
Because of these rather disappointing results this type of dynamic function test has not been widely adopted.
MATERNAL SERUM POLYPEPTIDE HORMONES
Human placental lactogen
Human placental lactogen (HPL), the name now internationally preferred to human chorionic somatomammotrophin(HCS) (Wolstenholme and Knight, 1972) , is synthesised by the syncytiotrophoblast of the placenta in large and increasing amounts during pregnancy. The output tends to remain constant during the last few weeks, and at term the placenta may be synthesising up to 12 g of HPL per day. HPL is first detectable in maternal serum at about six weeks gestation, and may reach one thousand times the normal levels of growth hormone with which it cross reacts immunologically. There is no circadian rhythm and its production is not affected by stress or metabolic changes Tyson et al., 1971) . It has a half-life of about 25 minutes and its measurement in maternal serum should therefore give a sensitive indication of placental biosynthetic function.
The method of choice for the measurement of HPL is radioimmunoassay, which gives adequate sensitivity with an incubation time as short as 30 minutes and can provide results within a few hours. A complement fixation test (Nakamura et al., 1970) and haemagglutination assay (Gusdon, 1969; Theppisai et al., 1971) have been proposed, but they are unlikely to replace radioimmunoassay because of inherent difficulties of precise quantitation.
HPL in the prediction of intrauterine fetal death (a) In the first and second trimesters
A number of workers have selected patients who were thought to have threatened abortion on clinical grounds and have performed HPL assays on the maternal serum. Genazzani et al. (1969; reported 24 such cases. Fourteen of these had a normal pattern of increasing serum HPL levels and went to term; nine patients had low and decreasing HPL levels and all spontaneously aborted within 17 weeks. The remaining patient had cervical incompetence and aborted, although HPL levels had been normal and rising. Saxena et al. (1969) also studied patients in the early part of pregnancy and reported low levels in five patients who later aborted. This was in agreement with the work of Singer et al. (1970) who reported five patients with low serum HPL levels, all of whom aborted within 20 weeks, and Spona and Janisch (1971) with 48 cases of threatened abortion whose mean HPL levels during the first -and second -trimester were significantly lower than normal. All those patients with levels below the normal range aborted their pregnancies. Using an assay capable of measuring concentrations of less than 0.1 mg/I, Niven et al. (1972) established a normal range using the results from 634 pregnancies, and then performed assays on 236 patients admitted to hospital because of bleeding during the first two trimesters. In 141 patients who aborted on first admission the mean HPL level was significantly lower than normal from the ninth week onwards, although the prognostic value in individual cases was not discussed. The remaining 9S patients had normal HPL levels although 14 subsequently aborted and 12 had ectopic pregnancies. They concluded that HPL assays on this group of patients distinguished, rapidly and cheaply, those patients who required hospital care and those whose pregnancies were not in immediate danger.
(b) In the third trimester
In late pregnancy there appears to be little correlation between HPL levels and fetal distress. Singer et al. (1970) reported two patients with normal levels two weeks after intrauterine fetal death at 36 weeks and 38 weeks respectively, and Spellacy et al. (1970) and Samaan et al. (1969) have described gradual decreases of circulating maternal HPL following antepartum fetal death. Beck et al. (1965) studied 27 diabetic pregnancies and found no significant difference between the serum HPL levels in this group and those in uncomplicated pregnancies. Samaan et al. (1969) and Josimovich et al. (1970) agreed with this conclusion, as did Spona and Janisch (1971) , although the last authors found much greater day to day fluctuations in a diabetic patient than would normally be expected. Spellacy et al. (1967) and Genazzani et al. (1971) each reported a single case of a diabetic patient whose HPL levels decreased immediately prior to fetal death in utero. Spellacy et al. (1971) later found that maternal HPL levels in 33 diabetic pregnancies were within their normal range, but four patients with normal levels produced stillbirths and the only fetal death associated with low levels of HPL was also complicated by maternal hypertension. Elevated levels of HPL were reported by Singer et al. (1970) in five out of 13 diabetic patients; in the one pregnancy which terminated unsuccessfully the mother had a normal HPL level at 35 weeks. Saxena et al. (1969) also described increased levels in a series of 12 diabetic mothers.
HPL levels in diabetic pregnancy
More recently, Ursell et al. (1973) performed serial measurements in 23 diabetic pregnancies with no evidence of placental dysfunction and reported a higher range than in normal pregnancies. In II cases with placental insufficiency the levels were significantly lower. They concluded that interpretation of results in diabetic pregnancies depends on a knowledge of the HPL levels normally associated with this particular complication; because of considerable overlap between groups with and without placental dysfunction they stress the need for serial assays at frequent intervals. Josimovich et al. (1970) found that 41 % of 17 toxaemic patients had low serum HPL levels although there was no correlation with the severity of the disease and all the babies survived. Spona and Janisch (1971) studied 37 cases of toxaemia and reported decreased levels at all stages of pregnancy as did Genazzani et al. (1971) after studying 53 subjects. They considered HPL determinations to be particularly valuable in this clinical condition. Spellacy et al. (1971) came to the same conclusion after studying 163 pregnant women with mild hypertension and 76 with severe hypertension. They found that eight of the mild toxaemic group had abnormally low HPL values as had 18 % in the severe group. Of the 14 fetal deaths occurring after 30 weeks gestation 13 had low HPL levels. Elevated levels in half of 12 patients with toxaemia were reported by Singer et al, (1970) , but these results have not been substantiated by other workers.
HPL levels in toxaemia
In a detailed study of over 300 patients, Letchworth and Chard (1972b) grouped their subjects according to parity and to the severity of toxaemia. They found, in agreement with most other workers, that the mean HPL levels in pre-eclamptic toxaemia are lower than that of normal subjects, a phenonemon which may be due to reduced placental volume which is common in patients with pre-eclampsia (Aherne and Dunnill, 1966) . In contrast to Spellacy et al. (1971) , they found that patients with mild toxaemia had lower levels than those in the moderate or severely affected cases but they also found that the mean levels were lower in multiparous patients with toxaemia than in the primaparous patients, a distinction which had not been reported elsewhere. Multiparous patients who developed fetal complications had lower HPL levels than might have been expected from their condition, but this was not true of the primaparous patients. AIl the results were expressed as mean levels within the groups of patients, and the authors concluded that further evidence was needed before the true prognostic significance of HPL determinations in individual cases of pre-eclamptic toxaemia could be determined.
HPL in retarded fetal growth
There has also been some controversy about the value of HPL as an indicator of retarded fetal growth. Spellacy et al. (1966a) and Singer et al. (1970) sampled maternal serum at birth and found no correlation between infant weight and the HPL levels in 50 deliveries, but Spellacy et al. (1966b) later showed that wide fluctuations in circulating HPL levels occur after the onset of labour, thus invalidating their diagnostic significance. Josimovich et al. (1970) performed single HPL measurements at different stages in each of 15 pregnancies which resulted in small-for-dates babies. They found a low level in five, a normal level in eight, and an elevated level in two cases. Genazzani et al. (1971) , however, reported low HPL levels during the last trimester in fivewomen who were all delivered of babies weighing less than 2.5 kg. There was a significant positive correlation with fetal birth weight when HPL levels were assayed ten days before birth (Seppala and Ruoslahti, 1970) , and when serial HPL measurements were made after 36 weeks gestation (Letchworth et al., 1971; Spellacy et al., 1971) . Saxena et al. (1969) concluded that subnormal serum levels will almost invariably be found after 28 weeks in mothers of small-for-dates babies but, provided no sudden decrease occurs, there is unlikely to be serious fetal distress. Spellacy et al. (1971) studied 57 women with Rhesus incompatibility. During the last trimester, their mean serum HPL level was higher than normal and 15 stillbirths were not associated with abnormally low HPL levels. Genazzani et al. (1971) reported four cases of intrauterine fetal death in 14 patients. Two of the four showed diminished HPL levels prior to fetal death and two, both with hydropic fetuses and large placentas, were characterised by abnormally high levels of maternal HPL. an observation in agreement with a report by Singer et al. (1970) . Josimovich et al. (1970) and Singer et al. (1970) noticed unusual elevation of HPL levels in the amniotic fluid of Rhesus-sensitised pregnancies and suggested that this measurement may be a useful additional index, alongside bilirubin determinations, for the severity of the condition.
HPL levels in Rhesus incompatibility
HPL levels in prolonged pregnancy
In 45 prolonged pregnancies not demonstrating the postmaturity syndrome, there was no significant difference in maternal HPL levels from those of normal pregnancies, but in ten prolonged pregnancies where fetal distress was evident, but with no other complications, there were significant decreases in HPL levels prior to labour (Genazzani et al., 1971) . This decrease in 'at risk' prolonged pregnancies has also been reported by Gusdon (1969) in two cases and by Saxena et al. (1969) in four cases. Keller et al. (1971) considered their patients in 97 two groups. One group of 39 with severe fetoplacental distress included those subjects with two or more of the following signs: very abnormal heart action, fetal acidosis, meconium in liquor, extreme retardation of fetal growth, intrauterine death, or pronounced infarction of the placenta. The second group of 46 patients was judged to have normal feto-placental function. These workers made single maternal serum HPL measurements and claimed that these correctly predicted feto-placental distress in all cases, but that there was incorrect classification of 35 %of patients with normal function; the authors suggested that these 35 % may have had incipient unrevealed feto-placental distress ! Spellacy et al, (1972) performed serial HPL measurements on 1100 women with various complications of pregnancy. They found no significant correlation with fetal heart patterns during labour nor with the five minute Apgar score (Apgar, 1953) . They concluded that HPL assays did not help in the selection of patients needing biophysical monitoring nor did they correlate with the infants' neurological development
HPL in the prediction offetal distress
In contrast to most reports, which deal with high risk populations, Letchworth and Chard (l972a) studied 333 patients with no abnormal signs or symptoms and claimed that fetal distress during or immediately after labour could be predicted in a small proportion of these by serial measurements of maternal HPL. In the few patients who had low HPL levels, 30 % of those with one low HPL measurement showed fetal distress while the proportion rose to 50 %in those with two and 7 %in those with three consecutive low HPL values.
Reports so far have indicated a greater correlation between maternal HPL levels and fetal viability in early pregnancy than in the last trimester. At the latter stage, where a good diagnostic index is of most value to the clinician since he may be able to intervene successfully, HPL measurements appear to be of little value, particularly in Rhesus sensitised and diabetic pregnancies. In those complicated with toxaemia, HPL assays do appear to give a satisfactory index of feto-placental distress, particularly if serial measurements are performed, although Spellacy et al. (1972) maintain that there is still no evidence that the use of HPL assays improves perinatal survival.
The function of the placenta is largely independent of the fetus (Behrman et al., 1967) and HPL (and HCG) can be synthesized in the absence of a fetus, as in trophoblastic disease (Samaan et al., 1966) . That the placenta is a particularly robust organ is demonstrated by its ability to function and produce HPL under adverse conditions in vitro (Suwa and Friesen, 1969) . Similar resiliance in vivo is also shown by reports of continued production of HPL after intrauterine fetal death. HPL assays may provide a good index of the amount of viable trophoblast and of its functions, such as the transfer of metabolites and nutrients. If this viable mass becomes too small, so that conditions are incompatible with intrauterine life, then the HPL assay will also reflect fetal function; however, fetal function may be depressed without effect on the viable trophoblast and in this case HPL assays may give a false sense of security.
Human chorionic gonadotrophin
The human chorionic gonadotrophin (HCG) levels in maternal blood and urine rise rapidly to a peak between the 50th and 70th days of gestation. Both bioassay and immunoassay, which measures antigens of varying biological activity (Wilde, 1969) , suggest that the activity falls away in the second trimester with a small secondary peak between 30 and 36 weeks. There is a very wide 'normal' range of hormone levels at all stages of pregnancy. The hormone is elaborated by the syncytiotrophoblast and the fetus is not directly involved in its production. The measurement of HCG in maternal urine has been extensively used as a 'pregnancy test', Until about 12 years ago this test was performed by bioassay but is now carried out exclusively by immunological techniques.
The use of HCG assay as a test of placental function towards the end of pregnancy has been far more limited. Investigators employing bioassay methods tend to agree that such estimations have little or no value in terms of patient management. Loraine and Matthew (1950) , for instance, investigated 29 patients with pre-eclamptic toxaemia; they found that in severe toxaemia there was a rise in mean HCG excretion but that the change in this group was inconsistent. In diabetes, Loraine and Matthew (1954) found that 33 % of a group of 52 patients had abnormally high levels in urine or serum but that there was no relationship to clinical complication. Hughes et al. (1964) studied a group of 25 patients with threatened or habitual abortion and found again that urinary HCG assay in early pregnancy had no definite relationship to the clinical outcome of the pregnancy. Wide (1962) performed HCG assays on the urine of patients with threatened abortion using the immunological haemagglutination assay (Wide, 1960) . In early pregnancy, he found low HCG excretion in patients who eventually aborted, while those patients who proceeded to a normal delivery had an excretion within the normal range. After the fourth month of pregnancy, however, the prognostic value deteriorated as seven out of ten patients with normal HCG levels aborted spontaneously.
Similar results were obtained by Brody and Carlstrom (1962; 1965) , who assayed HCG in maternal serum using a complement fixation technique. In a group of 73 patients with threatened abortion in early pregnancy 50 subjects who had low serum HCG levels all aborted, whereas the 23 patients with normal values went to term. They concluded that low and falling levels of HCG indicated extensive placental damage and that maternal serum HCG assays were of considerable prognostic value in early pregnancy.
The failure of HCG assay to provide a reliable index of feto-placental function in late pregnancy was confirmed by Carlsson (1964) , who could not correlate maternal serum HCG assays with the outcome of pregnancy nor with the severity of the complication in patients with pre-eclamptic toxaemia; by Danielsson (1965) who found no change in excretion of HCG in prolonged pregnancy; and by Samaan et al. (1969) who could demonstrate no relationship between HCG levels and the outcome of pregnancy in patients with diabetes and toxaemia. The last authors did demonstrate greatly increased levels in Rhesus sensitised patients but the changes did not occur until the fetus was hydropic, and the results were therefore of little help in improving fetal prognosis. Saxena et al. (1969) indicated that the value of HCG assays in late pregnancy was purely retrospective when they reported two cases with maternal serum HCG levels in the normal range during the ten days prior to the occurrence of spontaneous abortion, the levels falling only after the termination of the pregnancy. This is in agreement with the work of Genazzani et al. (1969) who found that maternal urinary HCG excretion remained constant until the day of abortion and with that of Spona and Janisch (1971) who reported normal serum HCG levels in two patients immediately prior to loss of fetal viability, As with HPL, HCG measurements in maternal serum or urine appear to correlate with fetal prognosis better in early pregnancy than in late pregnancy. Although sensitive HCG assays have been available for longer than those for HPL (Wilde et al., 1964) , their value as an index of fetal viability has not been investigated so intensively. This is probably because the rise in HCG production is not maintained in normal pregnancy, as is that of HPL, and changes in the last trimester are more difficult to interpret. The considerations regarding fetal-independent placental metabolism (section 3.1.7) are, however, likely to apply equally to HPL and HCG.
MATERNAL SERUM ENZYMES
4./ Heat-stable alkaline phosphatase
An isoenzyme of alkaline phosphatase is present in maternal serum with progressively increasing activity during normal pregnancy. This isoenzyme (HSAPS) is produced by the placenta and is relatively heat-stable, a characteristic which makes it readily identified in the laboratory. There have been numerous attempts to use its measurement as an index of placental function and as an indication of impending fetal distress.
Much of the earlier work on the estimation of HSAPS followed the method recommended by Neale et al. (1965) , who heated the serum at 56°C for 30 min and then measured the remaining activity using phenyl phosphate as substrate at pH 10.2.
The work of Fishman and colleagues (Fishman and Ghosh, 1967; Fishman et al., 1968) clearly demonstrated that the liver and intestinal alkaline phosphatase were not completely inactivated at 56°C, and they suggested that heating at a temperature of 65°C for 5 min provided a more specific assay for HSAPS. They also demonstrated that the optimum pH for this enzyme was 10.7 and the optimum substrate concentration was 72 mmol/l (phenyl phosphate). If these conditions are followed, a relatively specific and sensitive assay for HSAPS is achieved.
As work using the lower inactivation temperature may provide misleading results, only that of those authors employing 65 cC will be considered here, Hunter et al. (1970) studied maternal serum HSAPS levels in 143 patients with pre-eclamptic toxaemia. In mild pre-eclampsia, the mean activity was consistently higher than normal in all subgroups selected on the basis of age, parity, and period of gestation. At week 30 however, only 59 % of the individual readings were above normal although this increased to 90 % at week 38. In moderate or severe toxaemia all patients showed higher than normal activities. Perhaps more important was the observation that in the majority of patients an abnormal elevation occurred some 4-6 weeks before any clinical signs of pre-eclampsia were evident, and that in some patients there was a sharp fall from previously elevated levels prior to intrauterine fetal death. They concluded that high levels in early pregnancy pointed to failing placental function and that a sudden change in activity, either a decrease or an increase, gave a forewarning of impending fetal deterioration and was therefore helpful in clinical management. Benster (1970) agreed that high activities at 28-32 weeks in apparently normal pregnancies were predictive of later pre-eclampsia.
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His results differed from those of Hunter et al. (1970) in that the activity in hypertensive patients, although high at 28-32 weeks, tended to lie within the normal range during the later stages of gestation.
Some authors have been very pessimistic about the prognostic value of HSAPS determinations. Elder (1971) found no correlation with fetal or placental weight, and concluded that HSAPS assays were of no value in the prediction of small-for-dates babies. He did concede, however, that a significant alteration in activity for a particular patient may be of value in predicting acute placental insufficiency. Curzen and Varma (1971) studied 100 patients with various complications of pregnancy. After delivery, 28 cases were recognized where there had been evidence of fetal distress, but since only 18 % of these had shown abnormal activities they concluded that the assay was of no value in predicting fetal distress, fetal dysmaturity, or the Apgar score at birth. Keller et al. (1971) compared five different biochemical methods for the detection of feto-placental distress. In their series 36 % of 39 patients with severely disturbed feto-placental function had normal serum HSAPS activity and 25 % of patients with normal function had abnormal activities. They concluded that maternal serum HSAPS reflected placental rather than fetal function, and since the serum HPL level gave a better index of placental function the use of HSAPS measurements could not be recommended. The variable results which have been reported by different authors and in different patients may be related to the heterogeneity of the heat-stable enzyme reported by Ghosh and Fishman (1968) and by Leroux and Perry (1970) . The latter authors isolated two heat-stable fractions from a crude placental extract by chromatography on Sephadex G-2oo. They also reported the presence of two fractions in maternal pregnancy serum, one which remained constant in activity and another which increased during gestation.
The detection of placental alkaline phosphatase by immunological techniques has been reported by Iino et al. (1972) and the isoenzyme has been quantitated in maternal serum by Sussman et al. (1968) , who assayed the total alkaline phosphatase before and after removal of the placental fraction by a double antibody precipitation technique. It is possible that the use of such techniques might result in more reliable and reproducible reports on the changes in abnormal pregnancies.
Cystine aminopeptidase (oxytocinase)
There are two oxytocinases originating in the syncytiotrophoblast of the placenta (Page et al., 1961) . During the course of normal pregnancy, the placenta produces these oxytocinases in increasing quantities and this is manifested in rapidly rising serum activities, particularly in the last trimester. It has been suggested that their function is to inactivate oxytocin in the serum and hence prevent the onset of premature labour.
Oxytocinase may be measured by biological assay or by biochemical methods employing substrates such as L-cystine-di-,B-naphthylamide (Tuppy and Nesvadba, 1957; Babuna and Yenen, 1966) or L-cystine-di-4-nitroanilide (Tovey, 1969) . These substrates are hydrolysed by a series of cystine arninopeptidases (CAP) which include the oxytocinases; the other peptidases are present in serum in only small amounts and the measurement of CAP activity during pregnancy substantially measures oxytocinase activity.
The main problems with the chemical methods have derived from the carcinogenicity of ,B-naphthylamine (the hydrolysis product of one of the substrates) and the difficulty in synthesising alternative substrates which might be useful. The poor solubility of the substrates has also presented difficulties, but these problems have recently been overcome by the development of a sensitive fluorimetric assay (Chapman et al., 1971) , by an automated kinetic method (Peeters, 1972) , and by the introduction of the new substrate S-benzyl-L-cystine-4-nitroanilide (Tovey et al., 1973) with increased solubility. A novel approach to the assay of oxytocinase has been described by Chard et al. (1970) , who followed the destruction of 131I-labelled oxytocin by measuring its ability to bind to specified oxytocin antibody. Klimek (1968) has shown that the pH optimum of oxytocinase activity changes from pH 6.0 in the first trimester to pH 7.8 in the third. He suggested that this may be due to a change in the ratio of isoenzymes and recommends simultaneous estimations at both pH values.
It is generally agreed that there is a wide range of 'normal' serum CAP activities. Kleiner et al. (1969) found that although the mean activity in 50 pregnancies producing dysmature infants was significantly lower than the mean, in normal pregnancies, only 18 of these subjects had activities below the normal range. Similarly Hensleigh and Krantz (1970) produced evidence of placental dysfunction in 7 patients out of a group of 174 who had normal serum CAP activities.
In a study of maternal serum CAP in diabetic pregnancies, Chapman et al. (1971) found that the enzyme activity increased more rapidly in these patients than in normal pregnancies, but they gave no information about the outcome of these pregnancies.
A number of groups have studied maternal CAP levels in patients with pre-eclamptic toxaemia. There appears to be little effect on enzyme activity in mild pre-eclampsia but reduced levels occur in moderate or severe toxaemia, although the differences are not always significant in individual patients (Josephides and Turkington, 1967) . Babuna and Yemen (1966) studied eight cases of toxaemia, five of which showed decreasing levels of CAP ending with intrauterine fetal death. Tovey (1969) reported plasma CAP activities which failed to show a normal rise in four patients with varying degrees of hypertension who were all delivered of babies with some degree of dysrnaturity, and Josephides and Turkington (1967) studied two patients with severe pre-eclampsia where there was a decrease in CAP activity before fetal death occurred, although in one of these cases there was a rise immediately prior to death which continued for a time after the termination. In a study of 50 pregnancies with various complications, Tovey et al. (1972) found serial assays helpful in 64 %and misleading in 28 %of these cases.
The relationship of CAP to placental function rather than fetal function was demonstrated by Tovey (1969) , who reported a case of an anencephalic infant dying in utero while the CAP activity remained elevated for five weeks after the estimated time of death; also by Babuna and Yemen (1966) who performed a therapeutic abortion, leaving the dead fetus and placenta in utero, and showed that the enzyme activity continued to rise for five days after the abortion.
If maternal plasma oxytocinase assays are employed, the trend in levels must be studied by serial determinations, but the evidence indicates that even when this is done normal levels of enzyme activity will give a false sense of security in some patients who are at risk.
Diamine oxidase
Maternal serum diamine oxidase activity has been measured in normal and complicated pregnancies by Southren et al. (1966a Southren et al. ( , 1966b Southren et al. ( , 1968 ) using a radioassay procedure with 14C-labelled putrescine as the substrate. They showed that there was a rapid rise in activity during the first trimester followed by a more gradual increase towards term. They reported a wide normal range and considerable day to day variation in individual subjects. In complicated pregnancies, they found that when the activity remained in the normal range and continued to rise during the first and second trimester, the pregnancies consistently continued to successful deliveries at term. A low or falling diamine oxidase activity in ear-ly pregnancy was associated with a significant number of miscarriages, although some such pregnancies did continue to successful deliveries. In pregnancies complicated by diabetes, the enzyme activities appeared to be related to the severity of the disease, but there was a poor COl relation with fetal survival. Thirty high risk patients were studied by Resnik and Levine (1969) , but they were unable to predict the outcome of these pregnancies by serial diarnine oxidase measurements.
MATERNAL SERUM PROTEINS
Alpha-fetoprotein
Alpha-fetoprotein was first detected in fetal liver, fetal serum, the serum of neonates, and in patients with certain types of malignant tumours, using relatively insensitive immunodiffusion techniques. It was not until the advent of a radioimmunoassay for this protein (Ruoslahti and Seppala, 1971 ) that it became possible to measure it in maternal serum throughout pregnancy. It was then established that the levels rose steadily during pregnancy, decreasing slightly at term (Seppala and Ruoslahti, 1972a) .
These workers (Seppala and Ruoslahti, 1973a ) studied plasma alpha-fetoprotein in the second half of 143 pregnancies and showed that nine out of 13 patients whose babies died in utero had excess levels and that the increase preceded fetal death by up to 14 days. In a group of 69 high risk pregnancies, 60 % of those with signs of fetal distress also had elevated levels, although the results indicate that the differentiation between normal pregnancies and those with fetal distress may be less clear cut in the last few weeks of pregnancy. Only 8 % of cases with normal placental function had abnormal alphafetoprotein levels.
In another study, Seppala and Ruoslahti (l972c) assessed the value of alpha-fetoprotein as a guide to threatened abortion during the first two trimesters. There was no significant difference in levels between 22 women who aborted during the first trimester and those who continued to term, although there was a significant difference in those who aborted during the second trimester, seven of whom had high levels and three abnormally low levels.
From this preliminary work, the authors suggested that the measurement of maternal alpha-fetoprotein could provide useful information of fetal viability. However, Purves et al, (1973) reported wide fluctuations in maternal serum alpha-fetoprotein in apparently normal pregnancies and no correlation between maternal serum and cord blood levels. These workers concluded that undue emphasis had been laid on the prognostic value of maternal serum 101 alpha-fetoprotein, particularly toward the end of pregnancy when delivery of a live infant may be possible. More work is necessary before these conflicting views can be resolved.
The importance of alpha-fetoprotein assays in the antenatal diagnosis of fetal neural tube malformations is discussed in Section 8.
Transferrin
Maletnlema and Eddy (1972) found a significant correlation between maternal serum transferrin at about 24 weeks and fetal birth weight in 81 pregnancies from an African population with a high incidence of malnutrition. They suggested that serum transferrin measurement is a better index of malnutrition than that of other proteins such as albumin or globulin. As fetal malnutrition and low birth weight are related to mortality, maternal transferrin assay may be a useful prognostic guide in undernourished populations.
INVESTIGATIONS ON AMNIOTIC FLUID
Studies relating to steroid and polypeptide hormone concentrations in amniotic fluid have been discussed under their respective headings in earlier sections.
Amniotic fluid phospholipids and respiratory distress syndrome
Respiratory distress syndrome (RDS) typically occurs in babies born after spontaneous premature labour or after early induction performed because of obstetric complications, particularly Rhesus sensitivity or diabetes. A deficiency of a lipoprotein conjugated mainly to dipalmitoylecithin (which acts as a pulmonary surfactant stabilizing the alveolar air spaces) was implicated in the aetiology of this disorder by Gluck et al. (1970) . As fetal lung secretions appear to accumulate in amniotic fluid (Scarpelli, 1967; Biggs et al., 1973) , the measurement of phospholipids in the liquor was proposed as a method of assessing fetal lung maturity (Gluck et al., 1971) . These authors demonstrated a gradual rise in amniotic fluio lecithin starting at about 26 weeks with a very rapid rise from 33 weeks to term in normal pregnancies. In contrast, the sphingomyelin concentration showed a gradual rise to 26 weeks, but then decreased slightly towards term. Gluck et al. (1971) suggested that the lecithinsphingomyelin ratio provided a useful index of fetal pulmonary maturation. Using a rapid thin layer chromatographic method they showed that the ratio was less than unity in the early part of preg-nancy, but increased sharply from the 33rd gestational week to give values at term of up to 10. Whitfield et al. (1972a) determined this ratio on samples collected within 48-h before delivery in 128 patients, most of whom were Rhesus sensitized. In 102 patients who had ratios greater than two there were no babies with RDS, but of those with values between 1.5 and 2, 25 % of the infants developed RDS and in those with ratios of less than 1.5, the incidence was 80%. Gerbie et al. (1972) studied 76 patients and found only two with ratios less than 1.5 after 32 weeks gestation, and both babies developed RDS. Similarly Sarkozi et ai. (l972b) reported that all 76 patients with ratios above 1.8 delivered normal babies and three patients with ratios less than 1.5 had infants which developed RDS. Similar agreement between lecithin-sphingomyelin ratios and fetal pulmonary activity was reported by Bryson et al. (1972 ), Hobbins et al, (1972 , and by Lemons and Jaffe (1973) who found that 95 % of a series of 130 ratios correctly predicted the maturity of the fetal lung, although two babies of diabetic mothers with 'mature' ratios within 6 days of birth did develop RDS. Whitfield and Sproule (1974) have, however, shown that in diabetic patients a fall in lecithin-sphingomyelin ratio may follow the initial rise. The clinical outcome was related to the ratio at parturition thus emphasizing the importance of serial assays in such cases. Lemons and Jaffe (1973) also reported an interesting case of triplets, two of whom had RDS, where samples were taken from each amniotic sac; the ratio correctly predicted the outcome in each case.
In contrast, both Gudson and Waite (1972) using a colorimetric technique without chromatography, and Roux et al. (1972) using a modified chromatographic technique, reported a considerable number of low ratios with no concomitant signs of RDS in the infants. They concluded that the lecithinsphingomyelin ratio was not an accurate index for assessing fetal lung maturity. The method of Roux et al. (1972) , which incorporates important changes from the original technique, has been severely criticised by Gluck (1972) , who also pointed out the importance of rapid analysis or early freezing to prevent breakdown of lecithin by phosphodiesterases. Further methodological criticisms of some of the chromatographic procedures have been made by Gebhardt and Dubbeldam (1973) and Wagstaffe et al, (1974) , who have shown that the apparent lecithin-sphingomyelin ratio can show considerable variation, not only when different chromatographic media and different staining procedures are used but also when densitometric and planimetric quantitation are compared after the same spraying technique. It must be remembered also that the results from blood-stained samples should be interpreted with some care, since a 3 % contamination of red blood cells (containing phospholipids) will halve the lecithin-sphingomyelin ratio (Stein and Monaghan, 1973) . In addition, Spellacy et al. (1973) found that in patients treated with glucocorticoids there was a significantly greater rise in the ratio during the last few weeks in pregnancy, although they did not report the outcome of these pregnancies when delivered prematurely.
Attempts have been made to correlate quantitative amniotic fluid lecithin assay with fetal lung maturity. Nelson (1972) and Bhagwanani et al. (1972) eluted the lecithin spots from thin layer chromatograms and assayed the phosphorus content. Nelson measured amniotic fluid lecithin phosphorus at the time of delivery and reported low levels in ten cases resulting in RDS, but he also reported four cases with low levels out of 89 patients who delivered normal babies. Bhagwanani et al, found the predelivery amniotic fluid lecithin was less than 48 ftmol/l in all patients whose infants developed RDS; when it was above 54 ftmol/l all babies had normal pulmonary function.
It is claimed that quantitative lecithin assays offer two advantages over determination of the lecithinsphingomyelin ratio. One is that the precision of the measurement of ratios from thin layer chromatograms is poor and depends on the methodology; and the other is that the ratio method depends on the constancy of the extra-pulmonary sphingomyelin secretion (Biggs et al., 1973) which may vary, so giving misleading lecithin-sphingomyelin ratios (Nelson, 1972) . The disadvantages are that the methods of lecithin assay are time consuming and theoretically may give misleading results if there are excessively large or small amounts of amniotic fluid. It is known that the volume of amniotic fluid decreases after the 37th week, and this may contribute to the increasing concentration of lecithin. Falconer et al. (1973) claim that the total lecithin in the amniotic sac is of greater prognostic significance than the lecithin concentration alone, and that this measurement, which entails estimation of liquor volume by a dilution technique, is particularly valuable in borderline cases.
A rapid semi-quantitative 'bubble' or 'shake' test for surfactant in amniotic fluid had been proposed by Clements et al. (1972) . This test depends on the ability of the surfactant in diluted amniotic fluid samples to generate a stable foam in the presence of ethanol, which acts as a non-foaming competitive surfactant towards other components of amniotic fluid such as proteins, bile salts, and salts of free fatty acids which would normally produce foam. The end point of the test is the dilution which supports a stable ring of foam bubbles for at least 15 minutes after vigorous shaking. The advantage of this test is its speed and simplicity. Clements et al. (1972) reported 12 negative results (no bubble formation in low dilution) in 12 patients who had severe RDS; in 13 cases with intermediate results, eight infants exhibited a degree of pulmonary immaturity. All 68 patients with positive results (bubble formation at high dilution) were delivered ofnormal infants. Bhagwanani et al. (1973) compared the results of this test with lecithin determinations in 94 patients. The bubble test was positive in 37 patients whose infants were normal, but it was intermediate or negative in 43 other cases, although only eight of these showed evidence of pulmonary immaturity. The large number of false negatives probably arose because the 'bubble' test appears to be unreliable until about 37 weeks gestation, whereas lecithin assays are meaningful at an earlier stage when accurate assessment of lung maturity is more important.
Direct comparisons of the 'bubble' test with lecithin-sphingomyelin ratio (Wagstaffe and Bromham, 1973; Parkinson and Harvey, 1973: Whitfield et aI., 1972b) have shown that a negative or intermediate 'bubble' test should be interpreted with caution and that in such cases the liquor should be subjected to a chemical analysis. A positive 'bubble' test however indicates a very low risk of the development of respiratory distress syndrome provided that the test is performed in clean glassware on uncontaminated fresh (unfrozen) specimens.
Another approach to the estimation of pulmonary surfactant is to measure total palmitic acid in amniotic fluid (Warren et al., 1973) . Most of the palmitic acid is present as the dipalmitoyl ester of lecithin, and its measurement, after hydrolysis of the ester, is therefore an indirect assay of lecithin concentration. The advantages of this approach accrue from the precision and rapidity of the gas chromatographic methods for the assay of fatty acids. A preliminary evaluation of the technique has been reported by Warren et al. (1974) . The 32 cases where the babies developed respiratory distress syndrome were completely differentiated, by the liquor palmitic acid concentration, from 60 patients whose babies had mature lung function at birth. There were no borderline or intermediate cases.
Although the physiological basis for the various tests for fetal pulmonary maturity has recently been challenged by Condorelli et al. (1974) , who questioned the role of the fetal lung as a major contributor to amniotic fluid phospholipids, the tests when performed under controlled conditions, do appear reliable. The 'bubble' test should be regarded as a screening test, a negative result being confirmed by a chemical method. The most popular chemical method at present is the lecithin-sphingomyelin ratio, and it is not yet clear if lecithin or palmitic acid quantitation have sufficient advantages to supercede the ratio method. If some of the early work on the quantitative methods is confirmed, however, these techniques are likely to play an important future role in the assessment of fetal lung maturity.
Amniotic fluid assays for the assessment offetal maturity
As patients cannot always be certain of gestational times, particularly if they are taking oral contraceptives prior to conception, a number of indices have been proposed for the assessment of fetal maturity. Pitkin and Zwirek (1967) demonstrated that amniotic fluid creatinine concentration increased only gradually up to 34 weeks gestation but then rose sharply until term, at which time concentrations could be 3 to 4 times that in maternal plasma. The timing of this increase coincides with the activation of renal function within the fetus (Pitkin et al., 1968) . The measurement of creatinine concentration has not proved to be accurately predictive of fetal prematurity, but may bear a greater relationship to fetal size; thus Moore et al. (1971) obtained low levels in infants of low birth weight regardless of gestational age or maturity. Gerbie et al. (1972) also obtained a wide range of creatinine values, with many low results occurring in mature infants, and Roopnarinesingh and Morris (1971) showed that the mean creatinine values of pregnancies complicated by diabetes or pre-eclampsia were higher than normal. They concluded that the results of creatinine estimations are misleading in these groups ofpatients. The findings on patients with pre-eclampsia have been questioned by Harrison (1973) , who found no significant difference between this group and normal patients. There is, however, general agreement that in normal pregnancies an amniotic fluid creatinine level greater than 177 Io'ffioljl indicates that the pregnancy is almost certainly past 38 weeks gestation.
Amniotic fluid creatinine
Amniotic fluid osmolality
Amniotic fluid osmolality bears an inverse relationship to creatinine concentration, as increasing fetal renal function leads to a progressively more hypotonic urine reflecting the fall in sodium concentration (Lind et al., 1969) . As with creatinine, differences in fetal size and amniotic fluid volume reduce the prognostic accuracy of osmolality estimation. Miles and Pearson (1969) studied 72 normal or complicated pregnancies and found that an osmolality of 250 m osmol/I indicated that the pregnancy was of at least 38 weeks duration, but that higher values did not necessarily correlate with immaturity.
Amniotic fluid triglycerides
The estimation of fetal maturity by cytological examination of amniotic fluid for orange staining cells (Brosens and Gordon, 1966) is related to the functional maturity of the fetal sebaceous glands. Nelson and Freedman (1971) reasoned that the increase in triglyceride levels in amniotic fluid towards term reported by Biezenski et al. (1968) may also be a consequence of the maturation of these glands and may serve as an index of fetal maturity. They studied 96 patients; 24 had low triglyceride levels (less than 23 ,umol/l) and these included three patients who were delivered of immature babies, and four patients who had polyhydramnios. The authors concluded that low levels were of no prognostic significance. They also found poor correlation between triglyceride levels and the percentage of orange-staining cells, an indication that sebaceous glands were not wholly responsible for the appearance of both these amniotic fluid constituents. Sarkozi et al, (1972a) found that 6 out of 156 samples of amniotic fluid which they tested had high creatine kinase activity. In all six of these cases intrauterine death had already occurred. Eleven samples, including the above six, also showed large elevations of lactate dehydrogenase activity although the authors thought that the presence of this enzyme might have been due to erythrocyte contamination.
Amniotic fluid enzymes
Amniotic fluid alpha-fetoprotein
Alpha-fetoprotein is synthesized in the fetal liver. Levels of up to 25 rng/I can be detected in amniotic fluid collected during the second trimester, but the concentration measured by radioimmunoassay decreases to much lower levels (less than 300 ,ug/l at term (Seppala and Ruoslahti, I972b) . These authors demonstrated a significant correlation with gestational age during the third trimester in normal pregnancies, and suggested that alpha-fetoprotein measurement might prove useful in the estimation of gestation time. More recently Seppala and Ruoslahti (1973b) reported dramatic increases in amniotic fluid alpha-fetoprotein levels before intrauterine fetal death in the third trimester. Guibaud et al. (1973) concluded that an elevated level was often a sign of impending fetal death in early pregnancy. Brock and Sutcliffe (1972) have shown that anencephalic and spina bifida pregnancies also exhibit high amniotic fluid alpha-fetoprotein levels, and recent interest in this assay has concentrated on its use in the antenatal diagnosis of these congenital disorders (section 8).
Amniotic fluid hydroxyproline
Urinary hydroxyproline concentration is known to reflect growth rate in early infancy (Younoszai et al., 1967) . In an attempt to assess growth in utero the levels in amniotic fluid were determined by Wharton et al. (1971) , who found a gradual increase to a peak at about 28 weeks followed by a steady fall to term. The levels tended to be lower in pregnancies producing small-far-dates babies, but the normal range was too great for results to be of value in determining the maturity of the individual pregnancy.
Amniotic fluid citrate
Citrate is a normal constituent of human bones and Anteby et al. (1973) demonstrated a decrease in amniotic fluid citric acid during normal pregnancy, which may be related to bone formation in utero and therefore to fetal maturity. The scatter of values was wide, however, and the estimation unlikely to be of prognostic value.
Spectrophotometric examination of amniotic fluid for bilirubin
Bilirubin is present in amniotic fluid in the early stages of normal pregnancy. Mandelbaum et al. (1967) demonstrated a progressive decrease during pregnancy culminating in its disappearance at about 36 weeks. They showed that the bilirubin was not conjugated and suggested that the decrease may be due to increasing fetal liver function and ability to conjugate bilirubin; thus persistent bilirubin in amniotic fluid was a sign of fetal immaturity.
Chemical determinations of bilirubin in amniotic fluid are of little value as they are not sufficiently sensitive to detect the small amounts present even in pathological conditions. A spectrophotometric technique was investigated by Liley (1961; who showed good correlation between the peak absorption at 450 nm and the severity of haemolytic disease. However, the readings were the summation of the absorption of several pigments and of unavoidable turbidity, and a number of individual cases were reported in which the severity of the disease was not correctly predicted.
There have been many attempts to improve the spectrophotometric accuracy of this measurement by making it more specific for bilirubin. Some workers have measured the difference in absorption between the peak at 450 nm and a tangent drawn between the lowest point at each end of the curve, referring to this as the 'estimated' bilirubin (Walker et al.• 1964) . Because the position of the tangent is arbitrary, other workers have proposed the use of ratios of absorbance at different wavelengths on the absorbance curve (White et al., 1958; Walker et al.• 1964; Knox et al., 1965) . Fleming and Woolf (1965) took readings at four wavelengths and corrected for the presence of oxyhaemoglobin and turbidity, and also for methaemoglobin after reduction by sodium hydrosulphite; Ovenstone and Connon (1968) used a spectrophotometric method to measure the slope of the absorbance curve at 490 nm and correlated this with the bilirubin concentration. Another approach is that of Sewell (unpublished) who destroys bilirubin by photodecomposition and uses the resulting sample as a blank against which the bilirubin in an untreated specimen is measured at 460 nm.
Although it is generally agreed that there is good correlation between amniotic fluid bilirubin and the severity of haemolytic disease, accurate prediction does not appear to be possible in all cases of Rhesus sensitization. Walker et at. (1964) found that 12 % of patients with very high amniotic fluid bilirubin levels gave birth to infants which were not severely affected and 11 % of those with low levels had severe disease. Polacek et al. (1971) studied 40 Rhesussensitized patients and correctly predicted all severely affected infants, although three patients who were delivered of babies in good condition also had high bilirubin levels. Pomerance et al. (1968) established a reference range in Rhesus negative mothers with a normal outcome to their pregnancy. and after serial studies in 38 patients with haemolytic disease found that only 13 of the most severely affected patients had bilirubin levels consistently above the reference range; four out of the five which resulted in fetal or neonatal death, however, had a great excess of amniotic fluid bilirubin.
It may be that failure to interpret correctly the bilirubin levels in haemolytic disease against the changing physiological pattern has resulted in some of the inconsistencies reported. It is also possible, in isolated cases, that maternal jaundice may contribute to amniotic fluid bilirubin levels. Fort et al. 105 (1972) demonstrated high amniotic fluid levels in patients with sickle-cell disease at times of crisis near to term, although the fetus was normal in each case.
FETAL BLOOD pH AND ACID BASE BALANCE
Fetal scalp blood sampling was first described by Saling (1964) . This obstetric technique enables the fetal blood pH to be measured and used as an index of fetal hypoxia when other signs of fetal distress, such as meconium staining or abnormal fetal heart rate, are evident. The fetus becomes hypoxic either because the supply of oxygen from the mother is inadequate or because of compression of the umbilical cord during labour. When this happens, glycogen is utilized and lactic acid accumulates, causing a fall in pH, until anaerobic glycolysis itself is inhibited at around pH 6.9. This metabolic acidosis may be superimposed on a respiratory acidosis due to a reduction in excretion of carbon dioxide from the fetus. During normal birth there is a transient acidosis resulting in a fall of pH, possibly down to pH 7.25 (Saling, 1964) . pH values below this represent a 'pre-acidotic' stage (Bretsher and Saling, 1967) which should be monitored with care. A pH of 7.20 is usually regarded as a critical level at which obstetric intervention is indicated (Coltart et al., 1969) .
Fetal blood pH has been compared with the Apgar score at birth in a number of studies (Bowe et al., 1970; Kubli, 1968; Beard et al., 1967) . These studies showed that when the pH remained higher than 7.20, 85-90 % of the babies had Apgar scores above 7 and 10-15 % had scores below 6. When the pH fell to below 7.20, 30-55% had scores above 7 and 45-70 % recorded lower scores. An attempt to correlate fetal heart rate patterns with fetal blood pH was made by Kubli et at. (1969) . They found that when tachycardia was present, about 30% had pH values of less than 7.20 and when there were fetal heart rate changes, manifested in deceleration patterns, there was a definite correlation with the severity of the change and the disturbance in acidbase balance. Innocuous fetal heart rate patterns were concomitant with 94 % of pH values greater than 7.25. In similar studies Hon and Khazin (1969) showed a statistically significant increase in fetal base deficit with ominous fetal heart rate deceleration patterns.
The systematic application of fetal blood sampling has been confined to a few centres mainly because of the difficulties in training staff in the sampling techniques and in the need for continuous cover in the labour ward by medical staff if the technique is to be effective.
ANTENATAL DETECfION OF CONGENITAL
DISORDERS
While this review is principally concerned with biochemical tests directed towards the detection of impending fetal death or fetal dysmaturity, mention should be made of biochemical tests which, when applied during the gestation period, may be of predictive value in the detection of congenital disorders of the neonate. The application of these techniques, which may prompt either termination of the pregnancy or early treatment, may be expected to contribute to a reduction in infant morbidity.
There are a number of recessive disorders resulting from enzyme deficiencies, such as galatosaemia and homocystinuria. These disorders may be detected during gestation by measuring the enzyme activity in the cells from amniotic fluid either directly or after culturing. Work in this field has been extensively reviewed by Nyhan (1971) .
Congenital adrenal hyperplasia
A biochemical lesion which has attracted attention at the antenatal stage is that resulting in congenital adrenal hyperplasia, a condition where one of a variety of enzyme defects results in a reduced ability of the adrenal gland to synthesize cortisol. The hypothalamic-pituitary-adrenal axis attempts to compensate so that the production of corticosteroid precursors and androgens is increased. This process occurs in utero and some degree of masculinization of female fetuses results. After birth, adrenal hypofunction occurs and neonatal death commonly occurs unless replacement therapy with corticosteroids is available. If the fetuses of mothers from affected families can be screened, treatment of this potentially controllable condition in affected infants may be implemented at birth.
One of the first attempts at antenatal diagnosis of congenital adrenal hyperplasia was made by Jeffcoate et al. (1965) , who found high 17-oxosteroid and pregnanetriol (315 nmolfl) concentrations in amniotic fluid, collected near term, from a woman whose baby had congenital adrenal hyperplasia. In women who delivered normal babies, the pregnanetriol level was 68-136 nmol/I, Nichols and Gibson (1969) reported similarly high concentrations of pregnanetriol (270 and 338 nrnol/l) in amniotic fluid from two patients who delivered affected babies, but Merkatz et al. (1969) found raised values only after term in a prolonged pregnancy with an affected infant. In another such pregnancy, which ended at 37 weeks, the level of pregnanetriol in the amniotic fluid was within the normal range. In congenital adrenal hyperplasia of the neonate, the urinary pregnanetriol is often not elevated until several days after birth, possibly due to a gradual maturation of the adrenal gland (Mitchell and Shackleton, 1969) . The different levels of pregnanetriol in amniotic fluid in the cases reported may be a reflexion of a similar process in utero. Cathro et al. (1969) described a case with a 21hydroxylase deficiency which was associated with abnormally high excretion of oestriol in maternal urine, presumably due to excess androgen production by the fetal adrenal. Nichols and Gibson (1969) were unable to confirm these findings since they recorded normal oestrogen excretion in a woman whose fetus was subsequently shown to have a similar deficiency of 21-hydroxylase activity.
Results of measurements of pregnanetriol and androgens in amniotic fluid or oestriol in maternal urines have therefore so far been equivocal and further reports are awaited.
Central nervous system disorders
The antenatal detection of central nervous system disorders has recently attracted attention. Emery et al. (1972) showed that amniotic fluid levels of 5hydroxyindoleacetic acid were reduced in the second half of pregnancy where the infants had central nervous system malformations.
The same group (Emery et al., 1973) found abnormally high levels of amniotic fluid amino-acids in anencephalic pregnancies, particularly noting increases in the neutral amino-acids such as methionine, leucine, tyrosine, and phenylalanine. Macri et al. (1974) reported the immunological detection of cerebrospinal fluid f3 trace protein in the amniotic fluid from affected pregnancies, while this material was undetectable in control pregnancies. Another approach is that of Heys and Oakey (1973) who suggested that women with anencephalic fetuses may excrete significantly less 17-oxogenic steroid than do women with normal fetuses. Further investigations are required before these methods are fully assessed.
Recent interest has centred on the early antenatal diagnosis of neural tube defects, such as occur in anencephaly and myelocele spina bifida, by the detection of increased levels of amniotic fluid alpha-fetoprotein during the second trimester using electroimmunodiffusion techniques (Brock and Sutcliffe, 1972) . At this stage in pregnancy termination may be practical, and both Lorber et al. (1973) and Seller et al. (1973) have described the successful abortion of 20-week anencephalic fetuses on the basis of high alpha-fetoprotein levels coupled with sonographic investigations. There have also been other reports (Allan et al., 1973; Brock and Scrimgeour, 1972) where high amniotic fluid alphafetoprotein levels during the second trimester have led investigators to terminate pregnancies with fetal neural tube defects. No falsely high results were recorded in two series of 37 (Lorber et al., 1973) and 130 (Allan et al., 1973) unaffected pregnancies, although the less severe 'closed' myelocele spina bifida may not be detected. Many workers feel that amniotic fluid screening is now justified in 'at risk' patients who have previously had an affected child.
The possibility of assaying maternal serum rather than amniotic fluid was suggested by the report of Brock et al. (1973) , who described the second trimester diagnosis of an anencephalic pregnancy using a sensitive radioimmunoassay for alpha-fetoprotein measurement. This group (Brock et al., 1974) subsequently reported a retrospective study of 13 pregnancies. All these infants had neural tube defects; eight out of the eight with anencephaly and three out of five with spina bifida showed high maternal serum alpha-fetoprotein levels during pregnancy. Seller et al, (1974) did not obtain good discrimination between affected and normal pregnancies using this method, and they concluded that serum levels were less reliable than amniotic fluid assays. Harris et al, (1974) obtained normal results in eight out of nine affected pregnancies, and suggested that high maternal serumalpha-fetoprotein levels were more likely to be due to feto-placental dysfunction than to neural tube malformations per se.
It is therefore not yet clear if maternal serum alpha-fetoprotein measurement will prove an effective antenatal screen for neural tube malformations in the general population. At best it seems likely that only the more severely affected 'open' malformations will be detected (Harris et al., 1974) and other causes of high levels such as multiple pregnancies and nonneurological fetal abnormalities will have to be considered. Some of the present disagreement, however, may arise from differing reference ranges, varying times of blood sampling, and failure to classify the severity of the neural tube lesion. A clearer picture may emerge as these factors become defined.
DIRECT CoMPARISONS OF TESTS OF
FETO-PLACENTAL FUNCTION
Total oestrogen (oestriol) assays have recently enjoyed much popularity because the assay is relatively simple and capable of mechanization, and because the production of oestriol is dependent on the integrity of the whole fete-placental unit. However, a single index, such as urinary oestrogen excretion, does not always provide completely unambiguous information and this has resulted in a search for improved tests or combinations of tests.
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In many cases, attempts have been made to compare newly proposed assays with maternal oestrogen excretion, and a consideration of some of the findings is likely to indicate the best combinations of assays to perform in given situations.
When pregnanediol and oestrogen excretion were compared in patients with pre-eclamptic toxaemia and postmaturity syndrome (Strand, 1966) the assays appeared to give similar information, but the level of oestrogen usually gave an earlier warning of fetal distress than did that of pregnanediol. Coyle et al, (1962) detected significant changes in oestrogen excretion prior to fetal death in two cases where the pregnanediol excretion gave no indication that the fetus was in jeopardy. Maternal heat-stable alkaline phosphatase levels were compared with oestrogen excretion by Elder (1971) and by Curzen and Hensel (1972) and neither group could find a correlation between these assays in individual patients. This is perhaps not surprising, as fetal distress may be heralded by a rise or a fall in heatstable alkaline phosphatase levels (Hunter et al., 1970) . Both Curzen and Varma (1971) and Watney et al. (1970) after comparing these two tests concluded that urinary oestrogen gave a more reliable warning of fetal distress than did the alkaline phosphatase activity.
In another comparison of biochemical fetoplacental function tests, Watson et al. (1973) found that cysteine aminopeptidase, heat-stable alkaline phosphatase, and HPL were the least sensitive indicators of mild fete-placental dysfunction, and that the indices which involved a fetal contributionnamely, urine or serum oestrogen-were more efficient. This was in contrast to the conclusions of Chapman et al. (1971) , who felt that oestrogen excretion provided no more information with regard to fetal outcome than did the estimation of serum cystine aminopeptidase, and to those of Tovey et al. (1972) who also suggested that assays of this enzyme were of comparable overall value to those of urinary oestrogen. These investigators found that both assays were helpful in 60 % and misleading in 27 % of complicated pregnancies. In 10% of their patients neither assay was useful and they concluded that better diagnostic efficiency was achieved if both tests were performed. Petrucco et al. (1973) calculated a combined discriminant function using urinary oestrogen and plasma cystine aminopeptidase and found that its use was superior to either assay alone in the prediction of intrauterine growth retardation. Heat stable alkaline phosphatase results did not improve this discriminant. Keller et al. (1971) compared five different assays on patients with complicated pregnancies and concluded that both urinary oestrogen and serum HPL should be performed to achieve maximum correct prediction. In their hands, the HPL assay correctly predicted feto-placental distress in all cases while reliance on the oestrogen results would have missed 31% of these cases. However, oestrogen results were misleadingly low in only 12 %of patients having normal deliveries, whereas the HPL levels were low in 35 % of this group.
A different approach has been reported by Robinson et al. (1973) who used a scoring system for a number of biochemical tests, coupled with sonar cephalometry, for the assessment of fetal growth. They found that a combination of urinary oestrogen and sonar cephalometry gave the most reliable prediction of retardation of intrauterine growth; other combinations of tests, including cystine aminopeptidase and heat-stable alkaline phosphatase, were misleading.
CONCLUSIONS
Currently available tests for feto-placental function all yield fairly wide ranges of 'normal' values and there is frequently considerable overlap between these ranges and those found in pregnancies exhibiting feto-placental dysfunction. In addition, the appropriate normal range may not be the same in pregnancies with different complications. Thus, it has been shown that the range of HPL levels in pregnant patients with diabetes (Ursell et al., 1973) or with Rhesus incompatibility who are delivered of normal babies is higher than in uncomplicated pregnancies. Interlaboratory results may vary depending on the method used, as demonstrated clearly in the National Quality Control Scheme for urinary oestrogen, or on the standard used (there is no agreed international reference preparation for HPL), so reference ranges must be determined within each laboratory. These considerations mean that a single result of anyone method of assay rarely gives unequivocal information on feto-placental function. Results should be interpreted as an indication of the statistical chance that the fetus is in jeopardy. Serial assays will increase the statistical significance of the results in addition to indicating the trend, which is more important than the absolute value. The use of a combination of assays will also increase the statistical significance of the overall result providing the assays are chosen with care. In this respect the use of non-biochemical tests such as sonar cephalometry for assessing fetal growth should be considered.
At the present time, the assay of urinary oestrogens is still the most popular single method for assessment of feto-placental function in late pregnancy. No comparative studies have demonstrated a better overall indicator of fetal distress. As with other indices however, the process leading to oestriol production is complex and it is unlikely that all obstetric disorders will affect its metabolism in the same way.
Urinary chorionic gonadotrophin assay is a valuable indicator of placental development in very early gestation. Quantitative tests may be used to confirm early pregnancy, but quantitative assays in late pregnancy are of little value. Urinary pregnanediol and maternal serum heat stable alkaline phosphatase are now regarded as inefficient indices of feto-placental function and are generally considered to contribute little to the management of the patient. The value of oxytocinase assays is still in debate, but the results presented so far appear, at best, to give no more information than do oestrogen assays (Tovey et al., 1972) .
The interest in maternal serum human placental lactogen measurement as a test of placental function has recently increased considerably, principally due to the work of Spellacy in America and of Chard's group in Britain. The latter workers have studied large numbers of patients with each of the main complications of pregnancy and have been able to define reference ranges for each group. They have shown that while there are overall statistical differences between the levels in pregnancies where fetal distress is evident and those where it is not, the large overlap in each group makes it difficult to predict the outcome in individual cases. An important contribution was that made by Letchworth and Chard (1972a) when they studied normal pregnancies in addition to those which were clinical abnormal, and showed that HPL determinations correctly predicted many fetal problems manifesting themselves during labour and at delivery in both groups. A similar study by Beischer et al. (1968) showed that routine estimation of urinary oestrogen in an un selected population also predicted fetal complications at the time of delivery in the absence of other clinical signs. These findings suggest that it might be useful to perform biochemical screening on all patients in late pregnancy to indicate those who will need extra care during labour.
The sensitive assay for HPL described by Niven et al. (1972) is of value in determining which of those patients admitted with bleeding in early pregnancy are in danger of imminent abortion, so differentiating those patients needing hospitalization from those whose pregnancies are not in immediate danger. No other test of feto-placental function has been shown to be valuable in this situation.
Unlike other biochemical indices of feto-placental function which are produced by the combined metabolism of the fetus and placenta or by that of the placenta alone, alpha-fetoprotein is derived solely from the fetus. Although its measurement in maternal serum may be expected to provide information relating to the fetus which is independent of placental function, its value as an additional test of fetal viability in late pregnancy has not yet been substantiated. Statistically there appears to be a significant increase in maternal serum alphafetoprotein in pregnancies where the fetus is in jeopardy during the second and early third trimesters (Seppala and Ruoslahti, 1972a) and its measurement may prove to be of value at this stage. Changes in late pregnancy appear to be less significant, however.
Investigations on amniotic fluid are mainly directed at estimating fetal maturity as a guide to optimum timing of induction. A range of assays has been introduced to assess the development of a variety of metabolic functions of the fetus. The assay which appears to give the most useful information is the measurement of phospholipids and this is becoming a widely accepted index of fetal pulmonary maturity. With this particular assessment available, together with at least one other index of general feto-placental function, the obstetrician managing a complicated pregnancy can balance the risk, both to the mother and to the fetus, of inducing a premature baby.
Continued improvements in population health and in antenatal care during this century have led to a gradual reduction in fetal and neonatal mortality, which have now stabilized in Britain at around 12 and 10 deaths per WOO live births respectively (Registrar General 1971) . These numbers are now at a level where little further improvement can be expected and emphasis has centred on improving the quality of life of the offspring.
Biochemical tests have become an integral part of antenatal care only during the last decade. They have contributed to the improved perinatal mortality figures by promoting early induction in some patients being monitored because of complications of pregnancy; and by giving the obstetrician confidence to allow the fetus to continue development in utero, thus avoiding unnecessary prematurity, in other difficult pregnancies. In addition, biochemical tests have an increasingly important part to play in the reduction of perirlatal morbidity. They can help by alerting the obstetrician to incipient feto-p1acental distress, and by helping him achieve a well controlled gestation and normal delivery, with consequent reduction in neonatal morbidity, including the more subtle types such as mental retardation (Rhodes, 1973) ; they can also help to diagnose congenital disorders at a time when abortion is practical.
Finally, although this is a rapidly advancing field, it is interesting to predict the form which a future 109 comprehensive biochemical service for the monitoring of fete-placental function might take. In the first and early second trimester, tests for the diagnosis of congenital disorders such as alpha-fetoprotein assays would be available. These might be used for screening patients particularly at risk (amniotic fluid) or for screening the general obstetric population (maternal serum). In the second trimester, placental insufficiency and the likelihood of fetal jeopardy might be monitored by a sensitive serum HPL or alpha-fetoprotein assay. An index of general feto-placental dysfunction would be available for serial assays during the third trimester; the most reliable at present is urinary oestrogen, although plasma oestrogen assays may be preferred in the future. A placental function test such as maternal serum HPL or oxytocinase might also be available for monitoring during the third trimester. In order to detect incipient feto-placental dysfunction, either oestrogen or HPL assays would need to be performed at intervals during the third trimester in all pregnancies. To provide a guide to the optimum time for delivery in difficult pregnancies, amniotic fluid phospholipids should be available to monitor pulmonary function. During delivery, fetal acid base measurements might be performed on cases where fetal hypoxia was suspected.
Each of these tests is at present in use in some hospitals; some have not yet been fully evaluated, and undoubtedly new techniques will be introduced. If the more widespread adoption of such tests can make even a small contribution to a continuing reduction in neonatal morbidity, the return will be worthwhile, both in economic and humanitarian terms.
